- Home
- IBOC vs VKTX Comparison
IBOC vs VKTX Comparison
Compare IBOC & VKTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IBOC
- VKTX
- Stock Information
- Founded
- IBOC 1966
- VKTX 2012
- Country
- IBOC United States
- VKTX United States
- Employees
- IBOC N/A
- VKTX N/A
- Industry
- IBOC Major Banks
- VKTX Biotechnology: Pharmaceutical Preparations
- Sector
- IBOC Finance
- VKTX Health Care
- Exchange
- IBOC Nasdaq
- VKTX Nasdaq
- Market Cap
- IBOC 3.8B
- VKTX 3.5B
- IPO Year
- IBOC N/A
- VKTX 2015
- Fundamental
- Price
- IBOC $68.14
- VKTX $40.09
- Analyst Decision
- IBOC
- VKTX Strong Buy
- Analyst Count
- IBOC 0
- VKTX 13
- Target Price
- IBOC N/A
- VKTX $86.92
- AVG Volume (30 Days)
- IBOC 201.7K
- VKTX 4.6M
- Earning Date
- IBOC 08-07-2025
- VKTX 07-23-2025
- Dividend Yield
- IBOC 1.99%
- VKTX N/A
- EPS Growth
- IBOC 1.85
- VKTX N/A
- EPS
- IBOC 6.61
- VKTX N/A
- Revenue
- IBOC $808,643,000.00
- VKTX N/A
- Revenue This Year
- IBOC N/A
- VKTX N/A
- Revenue Next Year
- IBOC N/A
- VKTX $338.60
- P/E Ratio
- IBOC $10.72
- VKTX N/A
- Revenue Growth
- IBOC 1.28
- VKTX N/A
- 52 Week Low
- IBOC $54.11
- VKTX $18.92
- 52 Week High
- IBOC $76.91
- VKTX $81.73
- Technical
- Relative Strength Index (RSI)
- IBOC 51.86
- VKTX 70.98
- Support Level
- IBOC $68.35
- VKTX $39.35
- Resistance Level
- IBOC $71.83
- VKTX $41.68
- Average True Range (ATR)
- IBOC 1.50
- VKTX 2.02
- MACD
- IBOC -0.02
- VKTX 0.57
- Stochastic Oscillator
- IBOC 56.58
- VKTX 86.09
About IBOC International Bancshares Corporation
International Bancshares Corp is a multibank financial holding company. The company provides commercial and retail banking services in Texas and Oklahoma. The services provided by the bank include checking, savings, bank cards, lending, insurance, mortgage, investments, and other services.
About VKTX Viking Therapeutics Inc.
Viking Therapeutics Inc is a healthcare service provider. The company specializes in the area of biopharmaceutical development focused on metabolic and endocrine disorders. The company's clinical program pipeline consists of VK2809, VK5211, VK0214 products. VK2809 and VK0214 are orally available, tissue and receptor-subtype selective agonists of the thyroid hormone receptor beta. VK5211 is an orally available, non-steroidal selective androgen receptor modulator.